Immunome Inc. 8-K Filing

Ticker: IMNM · Form: 8-K · Filed: Dec 15, 2025 · CIK: 1472012

Immunome Inc. 8-K Filing Summary
FieldDetail
CompanyImmunome Inc. (IMNM)
Form Type8-K
Filed DateDec 15, 2025
Pages7
Reading Time8 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Immunome Inc. (ticker: IMNM) to the SEC on Dec 15, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.0001 (nge on which registered Common Stock, $0.0001 par value per share IMNM The Nasdaq).

How long is this filing?

Immunome Inc.'s 8-K filing is 7 pages with approximately 1,980 words. Estimated reading time is 8 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 1,980 words · 8 min read · ~7 pages · Grade level 13.2 · Accepted 2025-12-15 07:05:25

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMNM The Nasdaq

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements about the Company and its industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "vision," "objective," "anticipate," "believe," "estimate," "predict," "potential," "continue," "promising," "projected," "first step," "ongoing," or the negative of these terms, and similar words or expressions to identify these forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the Company's expected timing for submitting an NDA for varegacestat with the U.S. Food and Drug Administration; the Company's plans to provide additional data from the RINGSIDE trial; the benefits of HC74's design and its potential to be a best in class payload; and other statements regarding the management's intentions, plans, beliefs, expectations or forecasts for the future. These forward-looking statements are based on the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the risk that the RINGSIDE topline results are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data and such topline data may not accurately reflect the complete results of the trial; the risk that the Company's NDA submission for varegacestat is delayed based on regulatory feedback or otherwise, and that regulatory approvals for the Company's programs and product candidates are not obtained, are delayed o

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IMMUNOME, INC. Date: December 15, 2025 By: /s/ Max Rosett Max Rosett Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.